NEO Exchange

ESG Continues to Thrive With Mackenzie’s New Sustainable ETF, Now Trading on the NEO Exchange

Banking, Professional Services, Finance, ESG, Solution, TSX, ETF, IGM, Exchange, NEO Exchange, CEO, Awareness, NEO, Mackenzie Investments, SVP, Industry, Financial adviser, Security (finance)

Thursday, September 23, 2021 - 4:31pm

NEO welcomes Mackenzie Investments (Mackenzie) back to the NEO Exchange, with the launch of the Mackenzie Global Sustainable Bond ETF, an actively managed sustainable ETF.

Key Points:

NEO welcomes Mackenzie Investments (Mackenzie) back to the NEO Exchange, with the launch of the Mackenzie Global Sustainable Bond ETF, an actively managed sustainable ETF.
The launch of MGSB on the NEO Exchange is an exciting occasion for Mackenzie, remarked Michael Cooke, SVP and Head of Exchange Traded Funds at Mackenzie Investments.
We are very pleased to partner once again with Mackenzie Investments as they launch a new ESG solution on the NEO Exchange.
The NEO Exchange is a Canadian Tier 1 stock exchange for the innovation economy, bringing together investors and capital raisers within a fair, liquid, efficient, and service-oriented environment.

MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration

Thursday, September 23, 2021 - 12:30pm

These investigator-initiated studies are being conducted as part of MindMed's ongoing collaboration with the UHB Liechti Lab.

Key Points:

These investigator-initiated studies are being conducted as part of MindMed's ongoing collaboration with the UHB Liechti Lab.
This is the first direct clinical evidence demonstrating the equivalence of psilocybin and LSD on acute psychedelic effects.
"While both LSD and psilocybin have a long history in psychiatric research, psilocybin is being studied in a majority of ongoing clinical trials of psychedelics," said Dr. Liechti.
MindMed CEO Robert Barrow said, "Investors and researchers alike are eager to understand the similarities between psilocybin and LSD.

GetSwift Partners with Uber

Tuesday, September 21, 2021 - 1:30pm

GetSwift Technologies Limited (NEO: GSW) (GetSwift or the Company) is pleased to announce that today it has signed a partnership agreement with Uber Technologies, Inc (Uber) to integrate and offer a suite of best-in-class products and services.

Key Points:

GetSwift Technologies Limited (NEO: GSW) (GetSwift or the Company) is pleased to announce that today it has signed a partnership agreement with Uber Technologies, Inc (Uber) to integrate and offer a suite of best-in-class products and services.
GetSwift and Uber over the next few months will integrate their product offerings so that clients will be able to use the GetSwift product suite knowing that their data, customer interaction and payments are secured by GetSwift, in effect protecting their brand equity while benefiting from everything that is amazing about Uber.
Providing delivery as a service to merchants around the world is an Uber priority, and we are happy to be partnering with GetSwift to bring the best of Ubers logistics network to its new and existing customers, said Pooja Daftary, head of Uber Direct at Uber.
Forward-looking Statements in this press release include statements related to the ability of the Corporation and Uber to successfully complete the integration their product offerings, the anticipated timeline for the completion and deployment of the integration with Uber, the anticipated pricing of the GetSwift Offering following the completion of the integration with Uber, the anticipated features of the GetSwift Offering following completion of the integration with Uber and the potential impact on the Corporations clients, the geographic markets in which the integration will be introduced and deployed.

MindMed Announces Participation at Upcoming Investor Conferences

Tuesday, September 21, 2021 - 12:30pm

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness.

Key Points:

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness.
The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
Forward-looking information in this news release include, but are not limited to, statements regarding MindMed's participation in upcoming investor conferences.

NEO Exchange Enters Mining Industry With Public Listing of Greenland Resources

Monday, September 20, 2021 - 1:00pm

The NEO Exchange is proud to announce the public listing of Greenland Resources Inc. (Greenland Resources or the Company), a Canadian mining company focused on the development of its flagship project, the Malmbjerg molybdenum deposit in east-central Greenland.

Key Points:

The NEO Exchange is proud to announce the public listing of Greenland Resources Inc. (Greenland Resources or the Company), a Canadian mining company focused on the development of its flagship project, the Malmbjerg molybdenum deposit in east-central Greenland.
Greenland Resources is a milestone listing for the NEO Exchange.
With a focus on strategic minerals that are critical to the technologies of tomorrow, Greenland Resources is a fellow contributor to the innovation economy, like NEO.
Greenland Resources business is focused on the development of its 100% owned Climax type pure molybdenum deposit located in central east Greenland.

Awakn Life Sciences to Acquire Leading Ketamine-Assisted Psychotherapy Clinic in Norway

Thursday, September 16, 2021 - 12:53pm

Toronto, Ontario--(Newsfile Corp. - September 16, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a biotechnology company developing and delivering psychedelic medicine to treat addiction, is pleased to announce that it has signed a binding share exchange agreement to acquire a 100% interest in Axonklinikken AS ("Axon"), a leading ketamine-assisted psychotherapy clinic in Norway. As part of the transaction Axon will be renamed 'Awakn Oslo AS', and Axon's majority shareholder Dr. Lowan Stewart will be appointed as Regional Director for the Nordics and Managing Director Awakn Oslo AS.

Key Points:

"Our approach of development and delivery enables Awakn to earn revenue while we also develop a deep IP portfolio with strong commercial potential.
The new Oslo clinic will be led by Dr. Stewart, one of Europe's preeminent ketamine physicians.
Dr. Stewart was previously the founder and medical director of the Santa Fe Ketamine Clinic, the first ketamine treatment center in New Mexico.
About Awakn Life Sciences Corp.
Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic medicine to better treat addiction.

Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business Highlights

Wednesday, September 15, 2021 - 12:30pm

Toronto, Ontario--(Newsfile Corp. - September 15, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today is reporting its financial results and business highlights for the three and six months ended July 31, 2021.

Key Points:

Toronto, Ontario--(Newsfile Corp. - September 15, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today is reporting its financial results and business highlights for the three and six months ended July 31, 2021.
All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.
Anthony Tennyson, Chief Executive Officer of Awakn Life Sciences, commented, "Our team has achieved many accomplishments in a short period of time since going public in June of 2021.
About Awakn Life Sciences Corp.
Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction.

MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Friday, September 10, 2021 - 12:30pm

NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

Key Points:

NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
Members of management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the conference.
MindMed will maintain an archived replay of the webcast on its website for 30 days after the conference.
Forward-looking information in this news release include, but are not limited to, statements regarding the H.C. Wainwright 23rd Annual Global Investment Conference, management attendance at the conference and the ability of institutional investors to speak with members of MindMed's management.

Mountain Valley MD Holdings Announces Annual Shareholder Meeting

Thursday, September 9, 2021 - 9:01pm

TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the Company or MVMD) (CSE: MVMD) (FRA: 20MP) announces that the annual general and special meeting (the "Meeting") of holders (the "Shareholders") of common shares ("Common Shares") of MVMD is scheduled to be held virtually on September 21, 2021 at 11:30 a.m. Eastern Time.

Key Points:

TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the Company or MVMD) (CSE: MVMD) (FRA: 20MP) announces that the annual general and special meeting (the "Meeting") of holders (the "Shareholders") of common shares ("Common Shares") of MVMD is scheduled to be held virtually on September 21, 2021 at 11:30 a.m. Eastern Time.
Without approval, the Company would likely be required to wait until the next shareholder meeting or call a special meeting of the Shareholders, which would result in additional costs and timing complexity.
SOURCE: Mountain Valley MD Holdings Inc.
Certain statements contained in this news release may constitute forward-looking information.
Mountain Valley MD Holdings Inc.

Cybin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th

Biotechnology, Alternative Medicine, Health, Other Health

Thursday, September 9, 2021 - 11:50am

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Key Points:

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature.
Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials.
If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.